PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.20%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-6.44%
Negative gross profit growth while AVGO is at 0.51%. Joel Greenblatt would examine cost competitiveness or demand decline.
-6.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
0.69%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
-5.26%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-5.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.57%
Share count expansion well above AVGO's 0.26%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.27%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
2.54%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
4.31%
OCF growth at 50-75% of AVGO's 7.23%. Martin Whitman would question if the firm lags in monetizing sales effectively.
-94.07%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
137.93%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
76.91%
5Y revenue/share CAGR at 50-75% of AVGO's 122.61%. Martin Whitman would worry about a lagging mid-term growth trajectory.
71.38%
3Y revenue/share CAGR 1.25-1.5x AVGO's 60.90%. Bruce Berkowitz might see better product or regional expansions than the competitor.
No Data
No Data available this quarter, please select a different quarter.
-9.01%
Negative 5Y OCF/share CAGR while AVGO is at 73.80%. Joel Greenblatt would question the firm’s operational model or cost structure.
42.84%
3Y OCF/share CAGR 1.25-1.5x AVGO's 34.25%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
665.18%
Similar net income/share CAGR to AVGO's 691.11%. Walter Schloss would see parallel tailwinds or expansions for both firms.
548.82%
5Y net income/share CAGR at 75-90% of AVGO's 651.30%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
257.19%
3Y net income/share CAGR above 1.5x AVGO's 66.58%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
128.96%
Below 50% of AVGO's 839.21%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
49.99%
Below 50% of AVGO's 147.32%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
98.79%
3Y equity/share CAGR at 50-75% of AVGO's 188.08%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
4.56%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
23.92%
Below 50% of AVGO's 71.80%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
29.96%
3Y dividend/share CAGR at 75-90% of AVGO's 38.29%. Bill Ackman wants overhead or revenue enhancements to match competitor's dividend growth.
-5.71%
Firm’s AR is declining while AVGO shows 14.59%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
6.77%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
6.61%
Positive asset growth while AVGO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.79%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-6.21%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Our R&D shrinks while AVGO invests at 19.53%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
40.00%
SG&A growth well above AVGO's 14.12%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.